葛根素合用心先安治疗难治性心力衰竭的临床观察

目的 :探讨葛根素合用心先安治疗难治性心力衰竭的临床疗效。方法 :6 2例难治性心力衰竭患者随机分为对照组和治疗组。对照组常规治疗〔吸氧、利尿剂、洋地黄、血管扩张剂、血管紧张素转换酶抑制剂(ACEI)、控制感染和对症支持疗法〕。治疗组在常规治疗基础上 ,葛根素 0 .4 g加入质量分数为 5 %的葡萄糖2 5 0 ml,心先安 12 0 m g加入 5 %葡萄糖 2 5 0 ml静脉点滴 ,2周为 1个疗程 ,比较两组心功能的改善情况。结果 :两组治疗后心功能及心脏指数有显著改善 (P均 <0 .0 1) ,治疗组与对照组比较有明显差异 (P<0 .0 5 )。结论 :葛根素合用心先安治疗难治性心力衰竭疗效明显 ,安全可靠。

Clinical observation on effect of Puerarin(葛根素) combined with meglumine adenosine cyclophosphate in treatment of refractory heart failure

Objective: To explore the clinical effect of Puerarin combined with meglumine adenosine cyclophosphate in treatment of refractory heart failure. Methods: Sixtytwo cases with refractory heart failure were randomly divided into control group( n =30) and treatment group ( n =32). The control group was treated with routine therapy including oxygen inhalation, diuretic, digitalis, vasodilator, angiotensin converting enzyme inhibitor(ACEI), antibiotic therapy, and supporting treatment. The treatment group was treated with Puerarin 0.4 g+5% glucose 250 ml intravenously drip once a day for 14 days, meglumine adenosine cyclophosphate 120 mg+5% glucose 250 ml intravenously, drip once a day for 14 days, as well as routine therapy. After two weeks, the clinical effects were compared between two groups. Results: The heart function and cardiac indexes were improved after treatment in two groups (all P <0.01), the difference was significant between treatment group and control group after treatment ( P <0.05). Conclusion: Combined Puerarin with meglumine adenosine cyclophosphate in treating refractory heart failure is effective and safe.